San Antonio Breast Cancer Symposium

The TBCRC049 Trial for Treating Leptomeningeal Metastases in HER2+ Breast Cancer

December 14, 2019

Adam M. Brufsky, MD, PhD, FACP, discusses the TBCRC049 trial, which looks at the safety and efficacy of the tucatinib/trastuzumab/capecitabine combination to treat leptomeningeal metastases in HER2-positive breast cancer.

Subcutaneous Fixed-Dose and IV Pertuzumab/Trastuzumab Show Similar Efficacy and Safety in HER2+ Breast Cancer

December 13, 2019

In a 500-patient randomized trial, the pharmacokinetics, clinical activity, and safety of pertuzumab and trastuzumab administered as a subcutaneous fixed-dose combination were found to be noninferior to the intravenous versions of the drugs.

Durvalumab Regimen Shows Promise for Treatment of TNBC in the Neoadjuvant Setting

December 13, 2019

A pathologic complete response rate of 44% was observed with a neoadjuvant durvalumab (Imfinzi)-based regimen administered to patients with triple-negative breast cancer, according to results of a phase I/II study presented in a poster at the 2019 San Antonio Breast Cancer Symposium.

The monarcHER Trial in Advanced HR+, HER2+ Breast Cancer

December 13, 2019

Sara M. Tolaney, MD, MPH, discusses the results of the monarcHER trial, which examined adding the CDK4/6 inhibitor abemaciclib and endocrine therapy to trastuzumab versus trastuzumab plus chemotherapy in advanced hormone receptor-positive, HER2-positive breast cancer.

Preventative Breast Cancer Effect Maintained With Anastrozole in Long-Term Follow-Up Data

December 13, 2019

Nearly 12 years after discontinuing treatment, anastrozole, an aromatase inhibitor, maintained a preventive effect for postmenopausal women at high risk for breast cancer. Women assigned to anastrozole were 49% less likely to have developed breast cancer compared with women assigned to placebom according to data presented at the 2019 San Antonio Breast Cancer Symposium.

Addition of Atezolizumab Did Not Statistically Improve pCR in Triple-Negative Breast Cancer

December 13, 2019

Preliminary results from the phase III NeoTRIPaPDL1 Michelangelo study showed that the addition of atezolizumab to combination carboplatin plus nab-paclitaxel did not result in a statistically significant increase in the pathologic complete response rate compared with the combination alone in patients with early high-risk and locally advanced triple-negative breast cancer.

Risk of Recurrence Reduced With Dual Anti-HER2 Therapy in Breast Cancer

December 13, 2019

According to a pooled analysis of neoadjuvant trials presented at the San Antonio Breast Cancer Symposium, a pathologic complete response to HER2-directed neoadjuvant therapy reduced the risk of recurrence in patients with early HER2-positive breast cancer but did not eliminate it, supporting the common practice of continued anti-HER2 therapy.

Durvalumab Maintenance May Improve Outcomes in Triple-Negative Breast Cancer

December 13, 2019

In patients with triple-negative breast cancer or those with PD-L1–positive breast cancer across several subtypes, durvalumab as maintenance therapy, may improve outcomes compared with chemotherapy, according to an exploratory analyses from the phase II randomized SAFIR02-IMMUNO trial presented at the 2019 San Antonio Breast Cancer Symposium.

Pathologic Complete Response Rates in TNBC Benefit From the Addition of Pembrolizumab

December 12, 2019

The addition of pembrolizumab to standard-of-care chemotherapy for neoadjuvant and adjuvant treatment of early triple-negative breast cancer lead to higher rates of pathologic complete responses in the KEYNOTE-522 trial, especially in those patients with stage III and/or node-positive disease.

Palbociclib Real-World Data Hint OS Benefit in Frontline HR+/HER2- Breast Cancer

December 12, 2019

Frontline treatment with palbociclib demonstrated positive progression-free survival n real-world patients with HR-positive/HER2-negative metastatic breast cancer and may lead to an overall survival benefit , according to data from the pivotal PALOMA-2 trial.